Subscribe to “Palbociclib plus Aromatase- inhibitor as first-line treatment for Hormone Receptor (HR)-positive /Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer patients in Italy: a retrospective observational study (Palbo-Italy)”